InsiderClue
← All stocks

Arcutis Biotherapeutics, Inc.

ARQT Net buying
CIK 0001787306 #1713 in the set updated 17 Sep 2026
Bought (120 mo)
$71.63M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$60.70M
$16.30M on a plan · $12.65M straight out of an exercise
Sold at will
$31.74M
108 of 341 sales
Net
+$10.93M
+$39.89M against sales at will

By person

27 insiders · 400 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
SILVERSTEIN JONATHAN
Director
$21.90M (4)
—
+$21.90M
902,286
0.7179%
$22.58M
—
Frazier Life Sciences VIII, L.P.
10% owner
$13.70M (3)
—
+$13.70M
8,818,574
7.02%
$220.69M
+1,465%
Watanabe Todd
See Remarks
$30.58K (3)
$9.30M (78) scheduled
−$9.27M
924,927
0.7359%
$23.15M
+70.8%
Heron Patrick J
Director
$9.07M (11)
—
+$9.07M
10,602,451
8.44%
$265.34M
+2,073%
Welgus Howard G.
Director
—
$6.55M (73) scheduled
−$6.55M
61,466
0.0489%
$1.54M
−56.1%
Burnett Patrick
See Remarks
—
$5.86M (53) scheduled
−$5.86M
117,592
0.0936%
$2.94M
—
Bain Capital Life Sciences Investors, LLC entity
10% owner
$5.00M (1)
—
+$5.00M
3,979,292
3.17%
$99.59M
—
ORBIMED ADVISORS LLC entity
10% owner
$21.90M (4)
$25.45M (8)
−$3.55M
1,317,428
1.05%
$32.97M
—
Matsuda Masaru
See Remarks
$18.54K (2)
$3.36M (35) scheduled
−$3.34M
116,182
0.0924%
$2.91M
+4,319%
CHAUDHURI BHASKAR
Director
—
$1.83M (12)
−$1.83M
917,807
0.7302%
$22.97M
+6.2%
Edwards Larry Todd
See Remarks
$7.77K (1)
$1.21M (10)
−$1.20M
175,178
0.1394%
$4.38M
+11,998%
OSBORNE DAVID W
Chief Technical Officer
—
$1.10M (12)
−$1.10M
331,332
0.2636%
$8.29M
+10.8%
Curran Terrie
Director
—
$1.08M (4) scheduled
−$1.08M
23,526
0.0187%
$588.76K
—
Leonard Keith R
Director
—
$997.19K (1) scheduled
−$997.19K
27,901
0.0222%
$698.25K
—
Krishnamohan Neha
Director
—
$939.49K (2) scheduled
−$939.49K
27,901
0.0222%
$698.25K
+2,165%
LIN SUE-JEAN
Director
—
$898.54K (2) scheduled
−$898.54K
27,567
0.0219%
$689.89K
+9,089%
Smither John W
Chief Financial Officer
—
$619.52K (13) scheduled
−$619.52K
98,080
0.0780%
$2.45M
+78.4%
Gilbert Halley E
Director
—
$455.44K (1) scheduled
−$455.44K
27,901
0.0222%
$698.25K
—
Burrows Scott L
Chief Financial Officer
—
$298.56K (8)
−$298.56K
59,115
0.0470%
$1.48M
+67.8%
Topper David Joseph
Chief Financial Officer
—
$261.96K (2) scheduled
−$261.96K
182,774
0.1454%
$4.57M
—
Vairavan Latha
SVP Chief Financial Officer
—
$149.77K (7) scheduled
−$149.77K
85,978
0.0684%
$2.15M
+90.6%
Turney Patricia A.
SVP, Operations
—
$116.57K (8)
−$116.57K
62,862
0.0500%
$1.57M
—
Lock Kenneth A.
Chief Commercial Officer
—
$116.22K (8)
−$116.22K
63,429
0.0505%
$1.59M
+1,545%
Moore Matthew Richard
SVP and Chief Business Officer
—
$104.95K (4) scheduled
−$104.95K
145,505
0.1158%
$3.64M
—
Munshi Amit
Director
—
—
—
9,799
0.0078%
$245.23K
+390.0%
Peetz Christopher
Director
—
—
—
4,315
0.0034%
$107.99K
—
TURNER JOSEPH L
Director
—
—
—
4,312
0.0034%
$107.91K
—

Individual transactions

18
Insider
Date
Role
Action
Shares
Price
Amount
Heron Patrick J
13 Jun 2025
Director
Buy indirect
2,646
$13.08
$34.61K
Heron Patrick J
5 Jun 2025
Director
Buy indirect
378
$13.41
$5.07K
Heron Patrick J
4 Jun 2025
Director
Buy indirect
1,890
$13.32
$25.18K
Heron Patrick J
22 May 2025
Director
Buy indirect
2,520
$13.65
$34.40K
Heron Patrick J
21 May 2025
Director
Buy indirect
2,520
$13.66
$34.42K
Heron Patrick J
15 May 2025
Director
Buy indirect
2,520
$13.62
$34.32K
Heron Patrick J
14 May 2025
Director
Buy indirect
6,300
$13.76
$86.69K
Heron Patrick J
13 May 2025
Director
Buy indirect
2,374
$13.76
$32.66K
Heron Patrick J
9 May 2025
Director
Buy indirect
6,300
$13.60
$85.69K
Watanabe Todd
30 Nov 2024
See Remarks
Buy
2,038
$7.11
$14.48K
Matsuda Masaru
30 Nov 2024
See Remarks
Buy
1,657
$7.11
$11.77K
Edwards Larry Todd
30 Nov 2024
See Remarks
Buy
1,093
$7.11
$7.77K
Watanabe Todd
31 May 2024
See Remarks
Buy
4,000
$1.69
$6.77K
Matsuda Masaru
31 May 2024
See Remarks
Buy
4,000
$1.69
$6.77K
Heron Patrick J
4 Mar 2024
Director
Buy indirect
21,052
$9.50
$199.99K
Frazier Life Sciences VIII, L.P.
24 Oct 2023
10% owner
Buy
80,000
$2.50
$200.00K
Watanabe Todd
31 May 2023
See Remarks
Buy
1,463
$6.38
$9.33K
Frazier Life Sciences VIII, L.P.
5 Aug 2022
10% owner
Buy
250,000
$20.00
$5.00M
Showing 250 of 400 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 390
Amendments (4/A) skipped 14
Filings about a different issuer 0
Unreadable filings 0
Joint filings 9
Sales on a Rule 10b5-1 plan 124
Sales straight out of an exercise 109
Sales at will 108
Transactions with no price 0
Shares from compensation/vesting 37,239,743
Sales filed before the plan box existed 97
History held since 3 Feb 2020